Follow Up of a Randomised Trial of Two Different Courses of Dexamethasone for Preterm Babies at Risk of Chronic Lung Disease

Overview

Journal Arch Dis Child Fetal Neonatal Ed

Specialties Gynecology & Obstetrics
Pediatrics

Date 2002 Mar 8

PMID 11882552

Citations 12

Authors

D L Armstrong

J Penrice

F H Bloomfield

D B Knight

J A Dezoete

J E Harding

Affiliations

Soon will be listed here.

Abstract

Objectives: To report 18 month outcome of a randomised trial of two courses of dexamethasone to prevent chronic lung disease of prematurity.

Study Design: Babies of birth weight 1250 g or less ventilated at 7 days of age were randomised to a 42 day reducing course (long) or a 3 day pulsed (pulse) course of dexamethasone. Growth, cardiovascular status, and respiratory and neurodevelopmental outcomes were assessed at 18 months.

Results: Seventy six babies were enrolled. Nine died and three were lost to follow up. Babies receiving the long course were weaned off oxygen more quickly than those receiving the pulse course (47% v 69% on oxygen at 28 days; p = 0.01), but there were no differences in 18 month outcomes. However, children averaged -1 SD for growth parameters, half had moderate or severe disability, and 35% and 19% respectively required oxygen at 36 weeks and discharge.

Conclusions: The dexamethasone course used did not influence long term outcome. However, entry criteria for this study selected a group of babies at high risk of poor long term outcome.

Citing Articles

Outcomes of postnatal systemic corticosteroids administration in ventilated preterm newborns: a systematic review of randomized controlled trials.

Boscarino G, Cardilli V, Conti M, Liguori F, Repole P, Parisi P Front Pediatr. 2024; 12:1344337.

PMID: 38419972 PMC: 10899705. DOI: 10.3389/fped.2024.1344337.

Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.

Hay S, Ovelman C, Zupancic J, Doyle L, Onland W, Konstantinidis M Cochrane Database Syst Rev. 2023; 8:CD013730.

PMID: 37650547 PMC: 10468918. DOI: 10.1002/14651858.CD013730.pub2.

Impact of postnatal dexamethasone timing on preterm mortality and bronchopulmonary dysplasia: a propensity score analysis.

Kwok T, Szatkowski L, Sharkey D Eur Respir J. 2023; 62(4).

PMID: 37591537 PMC: 10586235. DOI: 10.1183/13993003.00825-2023.

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Onland W, van de Loo M, Offringa M, van Kaam A Cochrane Database Syst Rev. 2023; 3:CD010941.

PMID: 36912887 PMC: 10015219. DOI: 10.1002/14651858.CD010941.pub3.

Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants.

Puia-Dumitrescu M, Wood T, Comstock B, Law J, German K, Perez K JAMA Netw Open. 2022; 5(3):e221947.

PMID: 35275165 PMC: 8917427. DOI: 10.1001/jamanetworkopen.2022.1947.

References

Papile L, Tyson J, Stoll B, Wright L, Donovan E, Bauer C . A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998; 338(16):1112-8. DOI: 10.1056/NEJM199804163381604. View

Marinelli K, Burke G, Herson V . Effects of dexamethasone on blood pressure in premature infants with bronchopulmonary dysplasia. J Pediatr. 1997; 130(4):594-602. DOI: 10.1016/s0022-3476(97)70244-0. View

Bloomfield F, Knight D, Harding J . Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. J Pediatr. 1998; 133(3):395-400. DOI: 10.1016/s0022-3476(98)70277-x. View

Bhuta T, Ohlsson A . Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1998; 79(1):F26-33. PMC: 1720811. DOI: 10.1136/fn.79.1.f26. View

OShea T, Kothadia J, Klinepeter K, Goldstein D, Jackson B, Weaver 3rd R . Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999; 104(1 Pt 1):15-21. DOI: 10.1542/peds.104.1.15. View

Cummings J, DEugenio D, Gross S . A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989; 320(23):1505-10. DOI: 10.1056/NEJM198906083202301. View

Tarnow-Mordi W, Mitra A . Postnatal dexamethasone in preterm infants is potentially lifesaving, but follow up studies are urgently needed. BMJ. 1999; 319(7222):1385-6. PMC: 1117123. DOI: 10.1136/bmj.319.7222.1385. View

Howard E, Benjamins J . DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during development. Brain Res. 1975; 92(1):73-87. DOI: 10.1016/0006-8993(75)90528-4. View

Roge C, Silverman N, Hart P, Ray R . Cardiac structure growth pattern determined by echocardiography. Circulation. 1978; 57(2):285-90. DOI: 10.1161/01.cir.57.2.285. View

10.

Breitweser J, Meyer R, Sperling M, Tsang R, Kaplan S . Cardiac septal hypertrophy in hyperinsulinemic infants. J Pediatr. 1980; 96(3 Pt 2):535-9. DOI: 10.1016/s0022-3476(80)80862-6. View

11.

Merritt T, Stuard I, Puccia J, Wood B, Edwards D, Finkelstein J . Newborn tracheal aspirate cytology: classification during respiratory distress syndrome and bronchopulmonary dysplasia. J Pediatr. 1981; 98(6):949-56. DOI: 10.1016/s0022-3476(81)80603-8. View

12.

Meisels S, Plunkett J, Roloff D, Pasick P, Stiefel G . Growth and development of preterm infants with respiratory distress syndrome and bronchopulmonary dysplasia. Pediatrics. 1986; 77(3):345-52. View

13.

KITCHEN W, Ford G, Rickards A, Lissenden J, Ryan M . Children of birth weight less than 1000 g: changing outcome between ages 2 and 5 years. J Pediatr. 1987; 110(2):283-8. DOI: 10.1016/s0022-3476(87)80174-9. View

14.

Wilson D, BALDWIN R, Ariagno R . A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infants. J Pediatr. 1988; 113(4):764-8. DOI: 10.1016/s0022-3476(88)80398-6. View

15.

Harkavy K, SCANLON J, Chowdhry P, Grylack L . Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial. J Pediatr. 1989; 115(6):979-83. DOI: 10.1016/s0022-3476(89)80754-1. View

16.

Skidmore M, Rivers A, Hack M . Increased risk of cerebral palsy among very low-birthweight infants with chronic lung disease. Dev Med Child Neurol. 1990; 32(4):325-32. DOI: 10.1111/j.1469-8749.1990.tb16944.x. View

17.

Michaelsen K, Skov L, Badsberg J, Jorgensen M . Short-term measurement of linear growth in preterm infants: validation of a hand-held knemometer. Pediatr Res. 1991; 30(5):464-8. DOI: 10.1203/00006450-199111000-00013. View

18.

Robertson C, Etches P, Goldson E, Kyle J . Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. Pediatrics. 1992; 89(3):365-72. View

19.

Groneck P, Oppermann M, Speer C . Levels of complement anaphylatoxin C5a in pulmonary effluent fluid of infants at risk for chronic lung disease and effects of dexamethasone treatment. Pediatr Res. 1993; 34(5):586-90. DOI: 10.1203/00006450-199311000-00006. View

20.

Durand M, Sardesai S, McEvoy C . Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics. 1995; 95(4):584-90. View